BioMarin Pharmaceutical | BMRN - Current Assets


BioMarin Pharmaceutical reported $4.61B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Moderna USD 5.82B 45M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026